Src and Caveolin-1 Reciprocally Regulate Metastasis via a Common Downstream Signaling Pathway in Bladder Cancer

Shibu Thomas¹, Jonathan B. Overdevest¹, Matthew D. Nitz¹, Paul D. Williams¹, Charles R. Owens¹, Marta Sanchez-Carbayo⁴, Henry F. Frierson³, Martin A. Schwartz², and Dan Theodorescu¹,⁵

Abstract

In bladder cancer, increased caveolin-1 (Cav-1) expression and decreased Src expression and kinase activity correlate with tumor aggressiveness. Here, we investigate the clinical and functional significance, if any, of this reciprocal expression in bladder cancer metastasis. We evaluated the ability of tumor Cav-1 and Src RNA and protein expression to predict outcome following cystectomy in 257 patients enrolled in two independent clinical studies. In both, high Cav-1 and low Src levels were associated with metastasis development. We overexpressed or depleted Cav-1 and Src protein levels in UMUC-3 and RT4 human bladder cancer cells and evaluated the effect of this on actin stress fibers, migration using Transwells, and lung metastasis following tail vein inoculation. Cav-1 depletion or expression of active Src in metastatic UMUC-3 cells decreases actin stress fibers, cell migration, and metastasis, while Cav-1 overexpression or Src depletion increased the migration of nonmetastatic RT4 cells. Biochemical studies indicated that Cav-1 mediates these effects via its phosphorylated form (pY14), whereas Src effects are mediated through phosphorylation of p190RhoGAP and these pathways converge to reduce activity of RhoA, RhoC, and Rho effector ROCK1. Treatment with a ROCK inhibitor reduced UMUC-3 lung metastasis in vivo, phenocopying the effect of Cav-1 depletion or expression of active Src. Src suppresses whereas Cav-1 promotes metastasis of bladder cancer through a pharmacologically tractable common downstream signaling pathway. Clinical evaluation of personalized therapy to suppress metastasis development based on Cav-1 and Src profiles seems warranted. Cancer Res; 71(3); 1-10. ©2010 AACR.

Introduction

Caveolin-1 (Cav-1) is the major coat protein of caveolae, membrane invaginations that play important roles in transport of cellular lipids, cell adhesion, and signal transduction (1, 2). Additionally, non-caveolar Cav-1 may carry out additional signaling or transport functions (3). Cav-1 regulates the activity of many signaling molecules involved in cancer initiation and progression including G-proteins, H-ras, proteinkinase C, integrins, nitric oxide synthase, and epidermal growth factor receptor (4). Cav-1 has been identified as a tumor suppressor in some cancers, whereas in others its expression is elevated and it promotes cell survival, adhesion, and migration (5, 6). Cav-1 expression is elevated in some breast and prostate cancers (5, 6), colon cancer, thyroid carcinoma, ovarian cancer, myeloma, pancreatic ductal adenocarcinoma, and lung cancer (7–11). In bladder cancer, Cav-1 expression is undetectable in benign urothelium, higher in urothelial carcinomas, and maximal in tumor cells in the invading front (12). Cav-1 expression is also correlated with tumor grade (13). However, these studies are all correlative hence, the functional role for Cav-1 in human tumor progression is unknown.

The c-Src tyrosine kinase promotes cell growth and migration, and its activity or expression is elevated in a number of human tumors (14). In striking contrast to other cancer types, the tyrosine kinase activity and expression of pp60c-Src is elevated in low-grade bladder lesions whereas high-grade cancers display decreased expression and kinase activity (15). These results suggest a different role of Src kinase activity in bladder cancer progression that remains unexplored. Here, we study the functional consequence of Src-mediated signaling in urothelial cancers to address this knowledge gap. Interestingly, Cav-1 was first described as the major substrate for Src in v-Src transformed cell lines (16, 17) and Cav-1 phosphorylated on Tyr4 (pY4 Cav-1) can either inhibit Src through the recruitment of C-terminal Src kinase (CSK; ref. 18) or promote Src activation through an unknown mechanism (19). Thus, although Src and Cav-1 are interconnected, they may have contextually different effects.

Authors’ Affiliations: Departments of ¹Molecular Physiology and Biological Physics, ²Microbiology, and ³Pathology, University of Virginia, Charlottesville, Virginia; ¹Tumor Markers Group, Molecular Pathology Programme, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro 3, Madrid, Spain; and ⁴University of Colorado Comprehensive Cancer Center, Aurora, Colorado

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Corresponding Author: Dan Theodorescu, University of Colorado Comprehensive Cancer Center, 13001 E. 17th Pl. M5-FF-434, Aurora, CO 80045. Phone: 303-724-7135; Fax: 303-724-3162; E-mail: dan.theodorescu@ucdenver.edu

doi: 10.1158/0008-5472.CAN-10-0730

©2010 American Association for Cancer Research.

www.aacrjournals.org

Published OnlineFirst December 10, 2010; DOI: 10.1158/0008-5472.CAN-10-0730
Here, we study the roles and interactions of Cav-1 and Src in models of human bladder cancer and identify a novel and pharmacologically tractable signaling pathway and associated biomarkers. These data lay the foundation for novel personalized clinical trials for patients with locally advanced bladder cancer at high risk of metastasis development.

Materials and Methods

Cell culture and statistics

All bladder cancer cell lines used except UMUC-3 Luc and Lul-2 were purchased from ATCC (Manassas), cultured and profiled as described (20). UMUC3-Luc cells were generated by transfecting pCMV-Lux and pBabe (21) into UMUC3 cells using Eugene 6.0 (Roche) and stably selected with puromycin (2 μg/mL). Iterative tail vein injections of UM3-Luc generated the highly lung metastatic UM3-derive called Lul-2 (Overdevest and Theodorescu, manuscript in preparation) as reported (22). UM3 Src cells and UM3-Src-DN cells were generated by stably transfecting Src-S27 and Src-DN constructs (23) in pcDNA 3.1 vector. Cav-1 short hairpin RNA (shRNA) stable UM3-cell line was generated by transfecting Cav-1 shRNA in PLKO1 vector (Sigma). Comparisons made using one-way ANOVA and Newman–Keuls test unless otherwise indicated.

Small interfering RNAs

Small interfering RNA (siRNA) duplexes were synthesized by Dharmacron as follows:

- Cav-1 siRNA duplex 1: 5'-AGACGAGCUGAGCGGAAGGA-3' (UMUC-3 series) Cancer Research

- Cav-1 siRNA duplex 2: 5'-CAUCACAGCCGAACTTTT-3' P190RhoGAP siRNA duplex: 5'-GAUCAGUUUGAGGACAG-3' Src siRNA duplex: 5'-ACUCGCCUUCCUAGGCUU-3'. Luciferase (GL2) siRNA: 5'-GTACGGAGGATCTCAG-3'.

Cav-1 siRNA duplex is described by Sunaga and colleagues (24). Luciferase (GL2) siRNA served as negative control. Bladder cancer cells were transfected with Cav-1 as well as GL-2 siRNA duplexes (100 nmol/L) using OligofectAMINE (Invitrogen).

Additional materials and methods

Detailed description of materials and methods can be found in Supplementary Information section.

Results

Cav-1 and Src are reciprocal biomarkers of human bladder cancer behavior

Immunohistochemical studies using human bladder cancer specimens showed that Cav-1 expression correlates with tumor aggressiveness (12, 13). Conversely, Src tyrosine kinase expression and activity decreases with tumor progression (15). However, no studies have examined both molecules in the same patient samples. To examine this relationship at the RNA level, we identified 2 bladder cancer studies in Oncomine (www.oncomine.org; refs. 25, 26) that measured expression of both Cav-1 and Src. These studies found that Src expression is higher in superficial and lower in invasive bladder cancers, whereas Cav-1 expression is lower in superficial and higher in invasive bladder cancers (Fig. 1A). Examination of a microarray from an additional data set human bladder cancer specimens (20) showed an inverse correlation (R = −0.69, P = 0.034) between Cav-1 and Src expression in the same tumors (Fig. 1B). We then evaluated the association of the overall survival following radical cystectomy with Cav-1 and Src mRNA expression in a study of 109 bladder cancer patients (26). Patients with high Cav-1 and low Src mRNA tumor expression had worse survival than those with low Cav-1 and high Src (Fig. 1C). As tumor recurrence after cystectomy is usually metastatic and in most cases incurable (27), overall survival is an accurate surrogate for metastasis development. The prognostic value of Cav-1 and Src protein expression in tumors was then evaluated using immunohistochemistry in a second independent cohort of 151 bladder cancer patients that had undergone radical cystectomy. These results showed that both high Cav-1 and low Src staining correlate with poor survival whereas reciprocal expression in both proteins (high Cav-1 and low Src) had no further impact on prognosis (Fig. 1D). Together, data from these 2 independent studies confirm the reciprocal role for these 2 proteins in metastasis and strongly support their utility as prognostic biomarkers in patients following cystectomy.

Next, we analyzed a panel of human bladder carcinoma cell lines derived from different stage tumors and having different invasive and metastatic behavior in animal models. We again observed an inverse relationship between Cav-1 and Src, where high Cav-1 and low Src were found in the more metastatic lines. For example, RNA (Supplementary Fig. S1A) and protein expression (Supplementary Fig. S1B) showed undetectable expression of Cav-1 and high expression of Src in the RT4 noninvasive urothelial carcinoma cell line, whereas Cav-1 was high and Src was low to undetectable in lines derived from muscle invasive (KU-7) or metastatic (UMUC-3 series) cancers. RT4 cells also displayed high levels of active Src (pY418-Src) and undetectable levels of Tyr phosphorylated Cav-1 (pY14-Cav-1), whereas aggressive cell lines had high pY14 Cav-1 and low to undetectable pY418 Src (Supplementary Fig. S1B). We also calculated the ratio of pY14 Cav-1 to total Cav-1 protein and pY418 Src to total Src protein from these immunoblots. Highly metastatic Lul-2 cells showed a 2-fold higher ratio compared with parental UMUC-3 or UMUC3 Luc cells (P = 0.0076; Supplementary Fig. SIC and D). Together, these data support a reciprocal relationship between Cav-1 and Src expression and activity.

Cav-1 and Src mediate migration and actin stress fibers in bladder cancer cells

pY14 Cav-1 localizes to membrane protrusions at the leading edge of migrating cells (28) and has been implicated in cell migration. Hence, we sought to determine if Cav-1 expression promotes migration of human bladder cancer cells. UMUC-3 and KU-7 cells were transfected with Cav-1 siRNA and Transwell migration was examined 24, 48, and 72 hours later. Cav-1 depletion dramatically reduced chemotaxis in the Boyden chamber assay for both cell lines in proportion to the
degree of Cav-1 knockdown at different times (Fig. 2A and Supplementary S2A). Cav-1 depletion has been associated with apoptosis (10). However, identical cells in plating controls maintained in parallel showed no change in cell number over the same time period after Cav-1 depletion (CyQUANT fluorescence UMUC-3 GL-2 97 ± 3.85; UMUC-3 Cav-1 siRNA 92 ± 4.32). Thus, effects on cell migration were not due to alteration in cell numbers.

Src promotes tumor progression in many systems (29). However, its reduced expression and activity as a function of urothelial tumor stage question such a role in this tumor type. Invasive and metastatic UMUC-3 bladder cancer cells stably transfected with active Src (c-Src527) displayed a greater than 30% reduction in Transwell migration compared with vector control transfected UMUC-3 cells (Fig. 2B). Although Cav-1 silencing in UMUC-3 cells reduced their migratory capacity, UMUC-3 Src cells were not significantly affected (P = 0.786; Supplementary Fig. S2C). Taken together, these data show Cav-1 and Src are causally involved in bladder tumor cell migration and have similar effects on the actin cytoskeleton.

**Cav-1 and Src modulate Rho GTPases through distinct yet convergent molecular pathways**

The effects on actin stress fibers and cell migration suggest that the Rho GTPases may be involved. Indeed, high expression of RhoA and RhoC, and their effector ROCK1 are associated with poor prognosis and poor patient survival in bladder cancers (30). Interestingly, when we evaluated RhoA, RhoC and ROCK1 mRNA (Supplementary Fig. S3A) and protein (Supplementary Fig. S3B) expression in the 5 human bladder carcinoma cell lines used earlier (Supplementary Fig. S1B), all 3 genes increased as a function of invasiveness. We therefore sought to determine if Cav-1 or Src controlled the levels or activity of these two GTPases. Cav-1 depletion or Src overexpression in UMUC-3 cells had no significant effect on control (irrelevant siRNA or empty vector, respectively) cells and overexpression of Src led to a noticeable reduction in stress fibers (Fig. 2C). No further reduction in stress fibers was noted with depletion of Cav-1 in Src overexpressing cells (P = 0.786; Supplementary Fig. S2C). Taken together, these data show Cav-1 and Src are causally involved in bladder tumor cell migration and have similar effects on the actin cytoskeleton.
on expression of RhoA (Supplementary Fig. S3E and F), RhoC or ROCK1 but led to a profound decrease in their activity (Fig. 3A and B). As activated Src can inhibit Rho via phosphorylation and activation of p190RhoGAP (19, 31), we evaluated this protein as well. Src overexpression in UMUC-3 cells increased phospho-p190RhoGAP, whereas Cav-1 depletion showed only a modest increase (Fig. 3A).

Tyr phosphorylated Cav-1 (pY14Cav-1) is present in focal adhesions of migrating cells and may directly interact with RhoA and RhoC (32, 33). Cav-1 depletion in UMUC-3 cells led to a corresponding and dramatic decrease of pY14 Cav-1 (Fig. 3A and Supplementary Fig. S3C). However, Src overexpression in UMUC-3 GL2–transfected cells 72 hours after transfection. Inset, Western analysis for Cav-1, pY14Cav-1, pY418 Src, total Src, and tubulin expression was carried out on lysates collected from cells used for Transwell migration at 72 hours after transfection. C, actin cytoskeletal staining with phalloidin-AlexaFluor 594 (red) 72 hours after transfection with Cav-1 siRNA or GL2 duplex. Magnification indicated.

to determine the importance of pY14 Cav-1 for RhoA and RhoC activity, we knocked down Cav-1 and rescued its expression using wild-type or nonphosphorylatable Y14F Cav-1. These experiments were carried out in both vector control and Src overexpressing UMUC-3 cells. Whereas wild-type Cav-1 restored RhoA and RhoC activity in knockdown cells, Cav-1 Y14F completely failed to rescue (Fig. 3C). It is worth noting that the profound increase in RhoGTPase activation after Cav-1 rescue corresponds to the increase in pY14 Cav-1, whereas the change in pY418 Src is minimal (Fig. 3C). Thus, pY14 Cav-1 is critical for Cav-1–dependent Rho activation in these cells.

Cav-1−/− mouse fibroblasts show constitutive activation of Src kinase (19), which suggests that in cells lacking Cav-1, active Src could increase p190RhoGAP activity to inhibit Rho. We therefore tested whether this occurs in bladder cancer by different approaches. UMUC-3 cells in which Cav-1 was depleted were treated with the Src inhibitor PP2 or cotransfected with p190RhoGAP siRNA. Cav-1-silenced cells showed
increased Src activity, a modest but reproducible increase in phospho-p190RhoGAP, and the expected decrease in Rho GTP loading compared with GL-2 siRNA-transfected cells. However, neither PP2 treatment, forced expression of dominant-negative mutant of Src (Src DN) nor siRNA-mediated p190RhoGAP depletion in Cav-1 knocked down cells restored Rho activity. This result shows that, although Cav-1 still affects Src activity, the pathway linking Cav-1 to Rho is largely independent of Src and p190RhoGAP (Fig. 3D).

Src overexpression did not seem to increase phosphorylation of Cav-1, however, we sought to determine the contribution of endogenous Src activity to Cav-1 phosphorylation in bladder cancer. A dose response with PP2 revealed a much steeper reduction in pY418 Src than pY14Cav-1 (Supplementary Fig. S3D). As Src, Fyn, and Abl have been shown to phosphorylate Cav-1 (34), and PP2 inhibits Src and Fyn, these results suggest that other kinases, possibly including Abl, may contribute to pY14Cav-1 levels in bladder cancer cells.

To complement the results carried out above in the metastatic cell line UMUC-3, we investigated whether noninvasive RT4 human urothelial cells that express abundant Src but lack Cav-1 (Supplementary Fig. S1A and B) show altered migration in response to Src inhibition or Cav-1 overexpression. Stable expression of Cav-1 increased migration by 42% whereas inhibiting Src with PP2 increased migration 47% (Fig. 4A). Depletion of Src with siRNA also increased migration 51% compared with GL-2–transfected RT4 cells (Fig. 4B). Conversely, introduction of nonphosphorylatable Y14F Cav-1 failed to increase migration (Fig. 4A) or activate Rho GTPases (Fig. 4C). These results confirm the importance of Tyr14 phosphorylation of Cav-1 in this pathway.

We next tested the role of p190RhoGAP in suppression of migration by Src in RT4 cells. Knocking down p190RhoGAP increased migration by 48% (Fig. 4B). Additionally, p190RhoGAP knockdown in RT4 cells increased RhoA and C activation to approximately the same extent as Cav-1 expression or Src inhibition (Fig. 4C and D). Importantly, simultaneous
expression of Cav-1 and Src blockade (PP2 or siRNA) provided additive effects on RhoA and RhoC activity but not p190RhoGAP phosphorylation (Fig. 4C and D). These data confirm that both Cav-1 and Src activate Rho predominantly through independent pathways to stimulate cell migration, but only Src acts through p190RhoGAP.

Given the association of ROCK1 expression with human bladder cancer progression (30), we tested its role in bladder cancer cell migration downstream of Rho. Treating RT4 cells with Y27632, a selective ROCK inhibitor (35), reduced the migration of untreated cells, Cav-1 overexpressors or Src-inhibited cells to the same level (Fig. 5A). Similarly, treatment of UMUC-3 cells with Y27632 strongly suppressed migration (Fig. 5B). In parallel experiments, Y27632 caused no change in cell number over the same time period, excluding cytotoxicity or changes in cell number (CyQUANT fluorescence UMUC-3 vehicle-treated 95 ± 6.1; UMUC-3 Y27632-treated 89.2 ± 8.35). These data suggest ROCK1 is a common downstream element that lies downstream of both Cav-1 and Src/p190RhoGAP (Fig. 5C).

**Cav-1 and Src are reciprocal regulators of lung colonization**

We next investigated whether Cav-1 and Src affect in vivo tumor growth and metastasis. UMUC-3 cells in which Cav-1 was stably depleted or Src was stably overexpressed were developed and characterized in vitro. Western analysis confirmed the expected expression pattern of Cav-1, pY14 Cav-1, Src and pY418 Src (Supplementary Fig. S4A). Cav-1 shRNA cells (Cav-1shRNA) showed a modest but significant reduction in both monolayer growth (P = 0.014) and soft agar colony formation (P = 0.0081; Supplementary Fig. S4B and C). Cav-1 depletion also resulted in a nearly 6-fold decrease in Matrigel invasion compared with vector control cells (Supplementary Fig. S4D). When injected subcutaneously into mice, UMUC-3 Cav-1 shRNA cells produced tumors that were slightly (38%) smaller compared with UMUC-3 pcDNA cells at 21 days after injection (P = 0.0134; Fig. 6A). Importantly, both pY14 Cav-1 and Rho GTP loading were maintained in vivo as determined in tissue excised from these tumors (Supplementary Fig. S4E). Expression of active Src in UMUC-3 cells marginally decreased in monolayer growth (14%, P = 0.014), anchorage independent growth (33%, P = 0.009) and subcutaneous growth (22%, P = 0.021) compared with vector controls (Supplementary Fig. S4B and C, and Fig. 6A). In contrast to these mild phenotypes, a more substantial reduction in Matrigel invasion was seen with overexpression of active Src (P = 0.0081; Supplementary Fig. S4D).

We next tested the effect of Cav-1 and Src expression on experimental lung metastasis by injecting bladder cancer cells into the tail veins of 6-week-old nude mice. At 8 weeks postinjection, 60% of the mice receiving the empty vector-
transfected UMUC-3 cells displayed visible lung metastases. Remarkably, only 10% of the mice receiving UMUC3-Src cells had metastases and none were detectable when Cav-1 depleted cells were inoculated (Supplementary Table S1). A more sensitive and quantitative analysis using PCR with a 12p human-specific probe (36) showed a drastic reduction in human genomic DNA in Src-overexpressors compared with vector controls (SEM 47.8 \times 10^2 vs. 4,320.2 \times 10^2 copies, P = 0.0081; Fig. 6B) no human genomic DNA was detected in the lungs of mice inoculated with Cav-1 shRNA UMUC-3 cells. To study the involvement of Src and Cav-1 model in bladder cancer metastasis in detail, we used an alternative approach. Stable Cav-1 knock-down and Src overexpressing MB49 mouse bladder cancer model cell lines were injected subcutaneously in C57B6 mice (37). Control MB49 cells injected mice displayed metastasis in lung and visceral organs 21 days after injection, whereas Cav-1 depleted cells failed to display any metastasis. Also, stable Src overexpressed MB49 cells showed a marked abrogation in their metastatic ability compared with control cells (Supplementary Fig. S5). These results once again established the significance of the proposed Cav-1-Src bladder cancer metastasis model.

Finally, we evaluated effects of ROCK inhibition on the metastatic colonization of the lung by bladder cancer cells by treating mice injected with highly metastatic Lul-2 human bladder cancer cells with Y27632 for a 28-day period. We observed approximately 80% to 90% reduction in lung colonization in the Y27632-treated group compared with the vehicle-treated group as assessed by bioluminescent imaging, visual lung examination and PCR using 12p probe (Fig. 6C). These results establish the therapeutic rationale of Rho-ROCK pathway blockade in bladder cancer metastasis. As this agent is approved for human use for the treatment of cerebral vasospasm, it provides a rapid path to safe evaluation of this agent in treatment of metastatic bladder cancer in high-risk patients.
Discussion

Cav-1 is a highly multifunctional protein that can make both positive and negative contributions to cancer progression and metastasis. In bladder cancer, Cav-1 expression is elevated at the onset of oncogenesis (12) and rises even further as a function of stage and grade (12, 13, 38). This finding is particularly relevant because metastatic urothelial carcinoma...
is associated with poor prognosis and there are presently few molecular markers to identify localized tumors with high metastatic potential (39). Thus, Cav-1 may be a clinically useful marker. Our results take this idea a step further by showing that Cav-1 makes a critical functional contribution to bladder cancer migration and metastasis. Thus, Cav-1 is both a biomarker and a driver of tumor progression.

Src was first identified as a proto-oncogene and is well known to promote cell growth and motility in many systems (40). A previous study showed that Src kinase activity is elevated in early-stage bladder cancer; however, it was lower in poorly differentiated urothelial carcinoma (15). These results raised some questions about the role of Src in urothelial cancer. Our data confirmed that Src is decreased in advanced bladder cancer and, in addition, showed that inhibiting Src expression or kinase activity increased migration and metastatic capability of bladder cancer cells. Thus, Src is a negative regulator of bladder cancer metastasis.

When Cav-1 and Src expression were analyzed in 2 independent cohorts of human bladder cancer specimens and a panel of cell lines, a striking inverse correlation was noted. Several links have been reported between Cav-1 and Src. Cav-1 is a substrate for nonreceptor tyrosine kinases, including Src (16, 17). Although we failed to observe any increase in Cav-1 phosphorylation followed by Src overexpression in metastatic UMUC-3 cells, Src depletion in nonmetastatic RT4 cells or inhibition of Src by PP2 in UMUC-3 cells moderately decreased pY14 Cav-1 levels, suggesting that Src is probably one of several kinases that mediate Cav-1 phosphorylation. Thus, other kinases such as Abl may be responsible for maintaining pY14 Cav-1 in bladder cancer cells (34). Furthermore, Cav-1 phosphorylated on Tyr14 (pY14 Cav-1) can inhibit Src through the recruitment of CSK (18). Some decrease in Src activity after Cav-1 expression was visible in UMUC-3 cells but not obvious in RT4 cells, confirming that this mechanism exists but is probably not a major determinant in bladder cancer. Thus, we considered alternative mechanisms by which Src and Cav-1 might interact.

Src regulates Rho family of GTPases, activating Rac and Cdc42 (41), and inhibiting Rho via activation of p190RhoGAP (19, 31). Consistent with published data (31, 42), we observed inhibition of RhoA and C activity by Src in both UMUC-3 and RT4 cells. Additional results support a model in which Src controls bladder cancer metastasis through p190 RhoGAP activation and subsequent inactivation of Rho and ROCK1. Interestingly, we also found that Cav-1 expression controls activation of Rho, in this case as a positive regulator. As with Src, ROCK1 was critical for Cav-1-induced cell motility and invasion. However, these effects required pY14 Cav-1 but were largely independent of Src and p190RhoGAP. Thus, both Src and Cav-1 control bladder cancer metastasis through a common pathway involving Rho and ROCK1 but do so via distinct upstream elements, which are likely of significance in most, but likely not all bladder cancers. Notwithstanding the 2 separate upstream pathways, our results indicate that inhibiting the Rho-ROCK pathway using Y27632 in vivo could be a viable therapeutic strategy in patients. This approach is particularly appealing and timely, as there are several Rho kinase inhibitors such as fasudil that are orally available, safe and approved for human use for treatment of cerebral vasospasm. This approach would permit rapid deployment of personalized adjuvant clinical studies in patients at high risk for metastasis development after radical cystectomy. The biomarkers developed here would be used for patient selection, optimizing the chances for therapeutic success.

In summary, these results provide a mechanistic explanation for our observed association of high Cav-1 and low Src expression with metastasis development and poor survival in human bladder tumors. This finding also shows the utility of Cav-1 and Src as predictive biomarkers of clinical outcome. Most importantly, it offers the opportunity for rapid translation of this molecular knowledge into personalized therapy.

Disclosure of Potential Conflicts of Interest

None of the authors have any financial conflict of interest that might be construed to influence the results or interpretation of the article.

Authors' Contributions

S. Thomas, J.B. Overdevest, M.D. Nitz, M.A. Schwartz, and D. Theodorescu designed the experiments and analyzed the data. S. Thomas, J.B. Overdevest, M. D. Nitz, P.D. Williams, C.R. Owens, M. Sanchez-Carbaya, and H.F. Frierson performed the experiments. S. Thomas, M.A. Schwartz, and D. Theodorescu wrote the manuscript.

Acknowledgments

The authors thank Drs. N. Balasubramanian for helpful suggestions, S.J. Parsons for providing Src constructs, and A.V. Somlyo for providing Y27632.

Grant Support

This work was supported by NIH grants T32DK069264 to S. Thomas and RO1CA075115 to D. Theodorescu.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 1, 2010; revised October 28, 2010; accepted November 23, 2010; published OnlineFirst December 10, 2010.

References


Src and Caveolin-1 Reciprocally Regulate Metastasis via a Common Downstream Signaling Pathway in Bladder Cancer

Shibu Thomas, Jonathan B. Overdevest, Matthew D. Nitz, et al.

Cancer Res  Published OnlineFirst December 10, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-0730

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/12/10/0008-5472.CAN-10-0730.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.